Epigenetics in Parkinson's Disease

Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. While hereditary forms account for 10-15% of cases, the majority of PD cases are sporadic, suggesting that environmental factors and epigenetic regulation play crucial roles in disease pathogenesis. Epigenetic modifications—heritable changes in gene expression without altering the DNA sequence—have emerged as critical regulators of PD susceptibility, progression, and phenotypic variability.

The reversible nature of epigenetic modifications makes them attractive therapeutic targets. Unlike genetic mutations, epigenetic changes can potentially be modulated through pharmacological interventions, lifestyle modifications, and targeted therapies. This page provides a comprehensive overview of epigenetic mechanisms in Parkinson’s disease, including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling.

Overview of Epigenetic Dysregulation in PD

flowchart TD
    Epigenetics_in_Parkinson_s_Dis["Epigenetics in Parkinsons Disease"]
    Epigenetics_in_Parkinson_s_Dis["Parkinson"]
    Epigenetics_in_Parkinson_s_Dis -->|"related to"| Epigenetics_in_Parkinson_s_Dis
    style Epigenetics_in_Parkinson_s_Dis fill:#81c784,stroke:#333,color:#000
    Epigenetics_in_Parkinson_s_Dis["Introduction"]
    Epigenetics_in_Parkinson_s_Dis -->|"related to"| Epigenetics_in_Parkinson_s_Dis
    style Epigenetics_in_Parkinson_s_Dis fill:#81c784,stroke:#333,color:#000
    Epigenetics_in_Parkinson_s_Dis["second"]
    Epigenetics_in_Parkinson_s_Dis -->|"related to"| Epigenetics_in_Parkinson_s_Dis
    style Epigenetics_in_Parkinson_s_Dis fill:#81c784,stroke:#333,color:#000
    style Epigenetics_in_Parkinson_s_Dis fill:#4fc3f7,stroke:#333,color:#000

Multiple epigenetic alterations have been documented in Parkinson’s disease, affecting both the central nervous system and peripheral tissues. These changes contribute to:

• Dysregulation of genes involved in alpha-synuclein metabolism

• Impaired mitochondrial function and quality control

• Neuroinflammation and glial activation

• Dopaminergic neuron vulnerability in the substantia nigra

• Protein aggregation and clearance pathway dysfunction

Research has identified both disease-specific epigenetic signatures and therapeutic targets that could potentially modify disease progression.

DNA Methylation in Parkinson’s Disease

DNA methylation involves the addition of a methyl group to cytosine residues in CpG dinucleotides, typically associated with gene silencing. In PD, both global and gene-specific methylation changes have been documented.

Alpha-Synuclein (SNCA) Methylation

The SNCA gene encodes alpha-synuclein, the main component of Lewy bodies. DNA methylation at the SNCA intron 1 regulates its expression:

• Hypomethylation of the SNCA intron 1 promoter region has been observed in PD brain tissue, leading to increased SNCA expression ^{1SNCA methylation in Parkinson's disease (2010)2010 · DOI 10.1002/mds.22893Open reference}

• The methyl-CpG binding protein MeCP2 regulates SNCA transcription through methylation-dependent mechanisms ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}

• Environmental factors including pesticides can alter SNCA methylation patterns ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}

PARK Gene Methylation

Several familial PD genes show altered methylation:

• LRRK2: Hypermethylation of the LRRK2 promoter has been reported in some PD cases, potentially modifying disease onset age ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}

• PARK2/Parkin: Aberrant methylation of the PRKN promoter contributes to reduced parkin expression in sporadic PD ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}

• PINK1: Methylation changes affect PINK1 transcription in dopaminergic neurons ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}

• GBA: Epigenetic regulation of glucocerebrosidase influences PD risk in GBA mutation carriers ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}

Global DNA Methylation Changes

• Global hypomethylation has been documented in PD brain regions, particularly in the substantia nigra ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}

• Peripheral blood mononuclear cells show distinct methylation patterns that may serve as biomarkers ^{9Blood methylation biomarkers in PD (2019)2019 · DOI 10.1002/mds.27855Open reference}

• The DNA methylation clock is altered in PD, with accelerated epigenetic aging observed in some studies ^{10Epigenetic clock in PD (2018)2018 · DOI 10.1002/mds.27381Open reference}

DNA Methylation and Environmental Risk Factors

Environmental exposures modify PD risk through epigenetic mechanisms:

• Pesticide exposure: Alters DNA methylation patterns in dopaminergic neurons ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}0

• Dietary factors: Methyl donor availability (folate, B vitamins) influences methylation status and PD risk ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}1

• Physical exercise: Reverses some methylation abnormalities in PD models ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}2

Therapeutic Implications

DNA methylation modifiers are being explored as disease-modifying therapies:

• DNMT inhibitors: 5-azacytidine and decitabine modulate SNCA expression ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}3

• Folinic acid: Being investigated to support methylation pathways in PD clinical trials ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}4

Histone Modifications in Parkinson’s Disease

Histone modifications include acetylation, methylation, phosphorylation, ubiquitination, and sumoylation, dynamically regulating chromatin structure and gene expression.

Histone Acetylation

Histone acetylation, primarily at lysine residues, is associated with transcriptional activation:

• Reduced H3K9ac (histone H3 lysine 9 acetylation) has been observed in PD models and patient tissue ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}5

• HDAC inhibitors such as valproic acid and SAHA show neuroprotective effects in PD models ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}6

• HDAC6 is particularly implicated in alpha-synuclein aggregation and autophagy regulation ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}7

Histone Methylation

Different histone methylation marks have distinct effects:

• H3K4me3: Generally associated with gene activation; altered in PD ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}8

• H3K27me3: Repressive mark; changes in this modification affect dopaminergic neuron survival ^{2MeCP2 and SNCA regulation (2016)2016 · DOI 10.1002/mds.26701Open reference}9

• H3K9me2: Linked to environmental stress response in PD models ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}0

Histone Phosphorylation

• H3S10 phosphorylation increases in response to cellular stress in PD ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}1

• Histone kinases such as Aurora kinase B are dysregulated ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}2

Histone Ubiquitination

• H2A/H2B ubiquitination contributes to transcriptional dysregulation in PD ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}3

• The balance between ubiquitination and deubiquitination affects protein clearance pathways ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}4

HDAC Classes in PD

The SIRT1 pathway is particularly relevant, with NAD+ precursor supplementation showing promise in PD models ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}5.

Non-Coding RNAs in Parkinson’s Disease

MicroRNAs (miRNAs), long non-coding RNAs (lncRNAs), and other non-coding RNAs regulate gene expression post-transcriptionally and play critical roles in PD pathogenesis.

MicroRNAs in PD

miR-7 and miR-153

• miR-7 directly targets SNCA mRNA, reducing alpha-synuclein expression ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}6

• miR-153 also suppresses SNCA translation ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}7

• Both miRNAs are downregulated in PD brain, contributing to SNCA overexpression ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}8

miR-124

• miR-124 is crucial for neuronal survival ^{3K或其它等, Pesticide exposure and DNA methylation (2018)2018 · DOI 10.3233/JPD-181313Open reference}9

• Its downregulation contributes to:

  • Increased inflammation in microglia ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}0

  • Impaired autophagy ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}1

  • Synaptic dysfunction ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}2

miR-29 Family

• miR-29a/b/c are reduced in PD and regulate multiple PD-related genes ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}3

• Target genes include those involved in apoptosis and mitochondrial function ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}4

Other Relevant miRNAs

Long Non-Coding RNAs (lncRNAs)

• NEAT1: Upregulated in PD, regulates neuroinflammation ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}5

• MALAT1: Involved in synaptic dysfunction ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}6

• HOTAIR: Altered expression affects dopaminergic neuron survival ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}7

Circular RNAs (circRNAs)

• circSNCA: Derived from SNCA gene, sponges miR-7 ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}8

• circHIPK3: Regulates neuronal viability ^{4LRRK2 methylation in PD (2019)2019 · DOI 10.1002/mds.27744Open reference}9

Non-Coding RNAs as Biomarkers

Peripheral miRNAs show promise as PD biomarkers:

• Reduced miR-29 levels in cerebrospinal fluid (CSF) correlate with disease progression ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}0

• Blood-based miRNA signatures distinguish PD from atypical parkinsonism ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}1

Chromatin Remodeling in Parkinson’s Disease

Chromatin remodeling complexes (SWI/SNF, ISWI, CHD, INO80) use ATP to slide, evict, or restructure nucleosomes, dynamically regulating gene accessibility.

SWI/SNF Complex Dysregulation

• BRG1 (SMARCA4) and BRM (SMARCA2) ATPases are affected in PD ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}2

• The SWI/SNF complex regulates expression of:

  • SNCA

  • Mitochondrial quality control genes

  • Neuroprotective factors ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}3

BAF Complexes

• Neuron-specific BAF (nBAF) complexes are essential for neuronal function ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}4

• Mutations in BAF subunit genes (SMARCB1, ARID1A) have been linked to neurodegeneration ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}5

NuRD Complex

• The NuRD (Nucleosome Remodeling Deacetylase) complex couples ATP-dependent remodeling with HDAC activity ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}6

• Its dysregulation contributes to transcriptional abnormalities in PD ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}7

Histone Replacement

• H3.3 variant incorporation (H3F3A, H3F3B) is altered in PD ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}8

• This affects gene expression programs in dopaminergic neurons ^{5PARKIN methylation in sporadic PD (2015)2015 · DOI 10.1002/mds.26276Open reference}9

Therapeutic Targeting

• Small molecule SWI/SNF modulators are being developed ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}0

• Epigenetic editing using CRISPR-dCas9 fusions offers potential for precise gene regulation ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}1

Epigenetic Clocks and Biological Aging in PD

Epigenetic clocks based on DNA methylation patterns estimate biological age:

• Accelerated epigenetic aging has been documented in PD ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}2

• The discrepancy between chronological and epigenetic age (“epigenetic age acceleration”) correlates with:

  • Disease severity ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}3

  • Cognitive decline ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}4

  • Treatment response ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}5

Exercise and Epigenetic Reprogramming

Physical exercise has profound epigenetic effects in PD:

• Reverses DNA methylation abnormalities in SNCA and other PD-related genes ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}6

• Modifies histone acetylation patterns, enhancing neuroplasticity ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}7

• Upregulates neurotrophic factors through epigenetic mechanisms ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}8

• Reduces neuroinflammation via miRNA regulation ^{6PINK1 epigenetic regulation (2017)2017 · DOI 10.1002/mds.26985Open reference}9

Therapeutic Approaches

HDAC Inhibitors

• Valproic acid: Shown to protect dopaminergic neurons ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}0

• SAHA (Vorinostat): Modulates gene expression ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}1

• MS-275 (Entinostat): Being investigated for PD ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}2

DNMT Modulators

• 5-azacytidine: Modulates SNCA methylation ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}3

• RG108: Non-nucleoside DNMT inhibitor ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}4

miRNA-Based Therapeutics

• miR-7 mimics: Reduce alpha-synuclein expression ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}5

• miR-124 upregulation: Promotes neuronal survival ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}6

• Antagomirs: Block pathogenic miRNAs ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}7

Epigenetic Editing

• CRISPR-dCas9-DNMT3A: Target-specific DNA methylation ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}8

• CRISPR-dCas9-p300: Histone acetylation editing ^{7GBA methylation in PD (2019)2019 · DOI 10.1002/mds.27840Open reference}9

Lifestyle Interventions

• Mediterranean diet: Influences epigenetic patterns ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}0

• Caloric restriction: Modifies sirtuin activity ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}1

• Stress reduction: Alters cortisol-related epigenetic changes ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}2

Biomarker Potential

Epigenetic modifications serve as potential biomarkers for PD:

• Blood DNA methylation signatures: Distinguish PD from controls ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}3

• CSF miRNA profiles: Correlate with disease progression ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}4

• Epigenetic age acceleration: Predicts cognitive decline ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}5

Cross-Disease Mechanisms

Epigenetic dysregulation in PD shares features with other neurodegenerative diseases:

• Alzheimer’s disease: Common pathways including DNA methylation changes

• Multiple system atrophy: Distinct epigenetic signatures ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}6

• Progressive supranuclear palsy: Unique chromatin remodeling patterns ^{8Global hypomethylation in PD brain (2014)2014 · DOI 10.1002/mds.26067Open reference}7

See Also

• DNA Methylation in Neurodegeneration

• Histone Modification Pathways in Neurodegeneration

• Non-coding RNAs in Neurodegeneration

• Chromatin Remodeling in Neurodegeneration

• Epigenetics in Alzheimer’s Disease

• Epigenetic Therapies for Neurodegeneration

• Alpha-Synuclein Aggregation Pathway

• Mitochondrial Dysfunction in Parkinson’s Disease

Confidence Assessment

• Evidence quality: High (extensive human post-mortem studies, iPSC models, and clinical data)

• Therapeutic translatability: Moderate to High (several approaches in clinical trials)

• Biomarker potential: High (peripheral blood and CSF markers under validation)